Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/193208
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOrtiz-Maldonado Gibson, Valentín-
dc.contributor.authorRives, Susana-
dc.contributor.authorEspañol Rego, Marta-
dc.contributor.authorAlonso Saladrigues, A.-
dc.contributor.authorMontoro, Mercedes-
dc.contributor.authorMagnano, Laura-
dc.contributor.authorGiné Soca, Eva-
dc.contributor.authorPascal i Capdevila, Mariona-
dc.contributor.authorDíaz Beyà, Marina-
dc.contributor.authorCastella, Maria-
dc.contributor.authorCatalà, Albert-
dc.contributor.authorFaura, Anna-
dc.contributor.authorRodríguez Lobato, Luis Gerardo-
dc.contributor.authorOliver Caldés, Aina-
dc.contributor.authorMartínez Roca, Alexandra-
dc.contributor.authorRovira, Montserrat-
dc.contributor.authorGonzález Navarro, Europa Azucena-
dc.contributor.authorOrtega, Juan Ramón-
dc.contributor.authorCid Vidal, Joan-
dc.contributor.authorLozano, Miquel-
dc.contributor.authorGarcía Rey, Enric-
dc.contributor.authorFernández, Sara-
dc.contributor.authorCastro Rebollo, Pedro-
dc.contributor.authorJordán García, Iolanda-
dc.contributor.authorVillamor i Casas, Neus-
dc.contributor.authorAymerich Gregorio, Marta-
dc.contributor.authorTorrebadell, Montserrat-
dc.contributor.authorDeyá, Angela-
dc.contributor.authorFernández de Larrea Rodríguez, Carlos José-
dc.contributor.authorBenítez-Ribas, Daniel-
dc.contributor.authorTrias, Esteve-
dc.contributor.authorVarea, Sara-
dc.contributor.authorCalvo Rojas, Gonzalo-
dc.contributor.authorEsteve, Jordi-
dc.contributor.authorUrbano Ispizua, Álvaro-
dc.contributor.authorJuan, Manel-
dc.contributor.authorDelgado, Julio (Delgado González)-
dc.date.accessioned2023-02-07T16:45:23Z-
dc.date.available2023-02-07T16:45:23Z-
dc.date.issued2021-12-01-
dc.identifier.issn2051-1426-
dc.identifier.urihttp://hdl.handle.net/2445/193208-
dc.description.abstractThe prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but these are generally transient unless followed by alloHCT. Chimeric antigen receptors (CAR) targeting CD19 have shown promising results in R/R ALL, and one of these products (tisagenlecleucel) has been approved for the treatment of patients with R/R ALL up to 25 years of age.-
dc.format.extent4 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBMJ Publishing Group-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1136/jitc-2021-003644-
dc.relation.ispartofJournal for ImmunoTherapy of Cancer , 2021, vol. 9, num. 12, p. e003644-
dc.relation.urihttps://doi.org/10.1136/jitc-2021-003644-
dc.rightscc-by-nc (c) Ortiz-Maldonado, Valentín et al., 2021-
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/-
dc.sourceArticles publicats en revistes (Medicina)-
dc.subject.classificationLeucèmia limfocítica crònica-
dc.subject.classificationCèl·lules canceroses-
dc.subject.classificationTeràpia cel·lular-
dc.subject.classificationAntígens CD-
dc.subject.classificationImmunoteràpia-
dc.subject.classificationReceptors cel·lulars-
dc.subject.otherChronic lymphocytic leukemia-
dc.subject.otherCancer cells-
dc.subject.otherCellular therapy-
dc.subject.otherCD antigens-
dc.subject.otherImmunotheraphy-
dc.subject.otherCell receptors-
dc.titleFactors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec718809-
dc.date.updated2023-02-07T16:45:23Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
718809.pdf571.93 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons